PMID- 35435125
OWN - NLM
STAT- MEDLINE
DCOM- 20220815
LR  - 20220815
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 33
IP  - 5
DP  - 2022 Aug
TI  - Drug survival analysis of dupilumab and cyclosporin in patients with atopic 
      dermatitis: a multicenter study.
PG  - 2670-2673
LID - 10.1080/09546634.2022.2067818 [doi]
AB  - Purpose: This study provides a comparative survival analysis between the only two 
      drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin, 
      and dupilumab.Materials and methods: A multicenter, retrospective study, was 
      performed to assess drug survival (DS) analysis by comparing cyclosporin (CsA) 
      and dupilumab in 247 AD adult patients. DS was determined through Kaplan Meier 
      survival analysis. For each patient, data regarding age, sex, medical history, 
      and, at every visit, concomitant medications or procedures, adverse events (AEs), 
      and Eczema Area and Severity Index (EASI) were registered.Results: At week 72, 
      32/247 patients (13.96%) of the dupilumab group had discontinued the drug after a 
      mean time of treatment of 35.27 +/- 11.61 weeks; therefore, the DS rate at W72 was 
      87.04%. The most frequent (13/32; 40.63%) reason of drug discontinuation was the 
      achievement of complete disease remission after a mean duration of treatment of 
      42.28 +/- 2.02 weeks. In CsA-treated patients, DS rate at W72 was 21.05% (20/95 
      patients). Sixty-seven out of 95 (70.53%) patients had discontinued the drug, 
      while 8/95 (8.42%) of them were lost to follow-up during the first 12 weeks of 
      treatment. The causes of withdrawal among the patients who stopped CsA were AEs 
      (28/67;41.79%).Conclusions: Dupilumab has a significant longer DS when compared 
      to CsA.
FAU - Napolitano, Maddalena
AU  - Napolitano M
AD  - Department of Medicine and Health Sciences Vincenzo Tiberio, University of 
      Molise, Campobasso, Italy.
FAU - Mariano, Maria
AU  - Mariano M
AD  - Department of Dermatology, San Gallicano Dermatological Institute - IRCCS, Rome, 
      Italy.
FAU - Cristaudo, Antonio
AU  - Cristaudo A
AD  - Department of Dermatology, San Gallicano Dermatological Institute - IRCCS, Rome, 
      Italy.
FAU - Dastoli, Stefano
AU  - Dastoli S
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
FAU - Di Guida, Adriana
AU  - Di Guida A
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - De Lucia, Mario
AU  - De Lucia M
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Guerrasio, Gianluca
AU  - Guerrasio G
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Nistico, Steven Paul
AU  - Nistico SP
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
FAU - Passante, Maria
AU  - Passante M
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
FAU - Pigliacelli, Flavia
AU  - Pigliacelli F
AD  - Department of Dermatology, San Gallicano Dermatological Institute - IRCCS, Rome, 
      Italy.
FAU - Fabbrocini, Gabriella
AU  - Fabbrocini G
AD  - Section of Dermatology, Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Napoli, Italy.
FAU - Patruno, Cataldo
AU  - Patruno C
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220728
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
RN  - 83HN0GTJ6D (Cyclosporine)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Cyclosporine/therapeutic use
MH  - *Dermatitis, Atopic/drug therapy
MH  - Humans
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Dupilumab
OT  - cyclosporine
OT  - drug survival
OT  - immunosuppressive therapies
OT  - safety
EDAT- 2022/04/19 06:00
MHDA- 2022/08/16 06:00
CRDT- 2022/04/18 08:40
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/08/16 06:00 [medline]
PHST- 2022/04/18 08:40 [entrez]
AID - 10.1080/09546634.2022.2067818 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2022 Aug;33(5):2670-2673. doi: 10.1080/09546634.2022.2067818. 
      Epub 2022 Jul 28.